Skip to main content

A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients

 Digital Record
Identifier: 101584929X43


  • Publication: April 1954


7 Pages


Here, Freis's team studied the effectiveness of pentapyrrolidinium (a ganglionic-blocking agent, also called pentolinium) as an antihypertensive treatment. They concluded that the drug had several advantages in the treatment of severe hypertension over another ganglionic-blocking agent, hexamethonium. The drug's attributes, longer duration of action, greater potency, and a more uniform response to oral administration, more than compensated for its side effects and the frequent need to adjust dosage.

Language of Materials


Original Profiles System Identifier


Source Category


Freis, Edward D., Edward A. Partenope, Lawrence S. Lilienfield, and John C. Rose. "A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients." Circulation IX, 4 (April 1954): 540-546. Article. 7 Images.


Physical Description

Physical Condition - Good

Collecting Area Details

Part of the Archives and Modern Manuscripts Collection Collecting Area

8600 Rockville Pike
Bldg 38/1E-21, MSC 3819
Bethesda MD 20894 US
1-888-FINDNLM (1-888-346-3656)